PDS Biotechnology
PDSB
53 hedge funds and large institutions have $139M invested in PDS Biotechnology in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 5 closing their positions.
271% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 7
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
28% more capital invested
Capital invested by funds: $109M → $139M (+$30.2M)
15% more funds holding
Funds holding: 46 → 53 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$14.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.19M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.78M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.28M |
| 5 |
NC
Nexthera Capital
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.17M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$633K |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$483K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$121K |
| 5 |
Asset Management One
Tokyo,
Japan
|
-$120K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $5.74K | +$4.95K | +28 | New |
|
|
AIM
52
Advantage Investment Management
Cedar Rapids,
Iowa
| $5K | – | – | – |
|
53
Bank of America
Charlotte,
North Carolina
| $3K | +$2.65K | +15 | New |
|
|
DCM
54
DAFNA Capital Management
Los Angeles,
California
| – | -$633K | -3,459 | Closed |
|
|
TC
55
TFS Capital
West Chester,
Pennsylvania
| – | -$121K | -664 | Closed |
|
56
D.E. Shaw & Co
New York
| – | -$112K | -613 | Closed |
|
57
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$110K | -600 | Closed |
|
|
WPC
58
White Pine Capital
Bloomington,
Minnesota
| – | -$106K | -581 | Closed |
|
PDSB Hedge Fund Activity: Q2 2016 in Review
53 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2016, worth a combined $139M — up 28% from $109M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PDSB positions and 5 closed out — a net gain of 7 holders — while 26 added to existing stakes and 7 trimmed.
The largest buyer was Janus Henderson Investors US, adding an estimated $14.3M. The largest seller was Fidelity Investments, cutting an estimated $8.17M.
- 53 institutional investors held PDS Biotechnology (PDSB) as of Q2 2016, up from 46 in Q1 2016.
- Funds reported $139M of PDS Biotechnology stock for Q2 2016, up 28% quarter-over-quarter.
- 12 funds opened new PDS Biotechnology positions in Q2 2016 and 5 closed out, a net change of +7 holders.
- The largest PDS Biotechnology buyer in Q2 2016 was Janus Henderson Investors US, an estimated $14.3M added.
- The largest PDS Biotechnology seller in Q2 2016 was Fidelity Investments, an estimated $8.17M sold.
Based on aggregated 13F filings for Q2 2016.